MA33768B1 - Triazolopyridines - Google Patents
TriazolopyridinesInfo
- Publication number
- MA33768B1 MA33768B1 MA34899A MA34899A MA33768B1 MA 33768 B1 MA33768 B1 MA 33768B1 MA 34899 A MA34899 A MA 34899A MA 34899 A MA34899 A MA 34899A MA 33768 B1 MA33768 B1 MA 33768B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- preparation
- relates
- formula
- triazolopyridines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Abstract
LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS TRIAZOLOPYRIDINES REPRÉSENTÉS PAR LA FORMULE GÉNÉRALE (I) QUI SONT DES INHIBITEURS DE LA KINASE DE FUSEAU MONOPOLAIRE 1 (MPS-1 OU TTK) : FORMULE (I), DANS LAQUELLE R1, R2, R3, R4 ET R5 SONT TELS QUE DONNÉS DANS LA DESCRIPTION ET LA REVENDICATION. L'INVENTION CONCERNE ÉGALEMENT DES PROCÉDÉS DE PRÉPARATION DESDITS COMPOSÉS, DES COMPOSITIONS ET DES COMBINAISONS PHARMACEUTIQUES QUI COMPORTENT LESDITS COMPOSÉS, L'UTILISATION DESDITS COMPOSÉS POUR LA FABRICATION D'UNE COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT OU LA PROPHYLAXIE DE MALADIES PROLIFÉRATIVES, AINSI QUE DES COMPOSÉS INTERMÉDIAIRES UTILES DANS LA PRÉPARATION DESDITS COMPOSÉS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09075535A EP2343297A1 (fr) | 2009-11-30 | 2009-11-30 | Triazolopyridines |
PCT/EP2010/006994 WO2011063908A1 (fr) | 2009-11-30 | 2010-11-17 | Triazolopyridines |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33768B1 true MA33768B1 (fr) | 2012-11-01 |
Family
ID=42028156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34899A MA33768B1 (fr) | 2009-11-30 | 2012-05-28 | Triazolopyridines |
Country Status (36)
Country | Link |
---|---|
US (1) | US9676766B2 (fr) |
EP (2) | EP2343297A1 (fr) |
JP (1) | JP5805653B2 (fr) |
KR (1) | KR20120115290A (fr) |
CN (1) | CN102762557B (fr) |
AR (1) | AR079166A1 (fr) |
AU (1) | AU2010324155B2 (fr) |
BR (1) | BR112012012906A2 (fr) |
CA (1) | CA2781915A1 (fr) |
CL (1) | CL2012001391A1 (fr) |
CR (1) | CR20120295A (fr) |
CU (1) | CU24100B1 (fr) |
CY (1) | CY1115866T1 (fr) |
DK (1) | DK2507235T3 (fr) |
DO (1) | DOP2012000150A (fr) |
EA (1) | EA022353B1 (fr) |
EC (1) | ECSP12011935A (fr) |
ES (1) | ES2525069T3 (fr) |
GT (1) | GT201200165A (fr) |
HK (1) | HK1178153A1 (fr) |
HN (1) | HN2012001162A (fr) |
HR (1) | HRP20141093T1 (fr) |
IL (1) | IL219750A (fr) |
MA (1) | MA33768B1 (fr) |
MX (1) | MX2012006252A (fr) |
MY (1) | MY160325A (fr) |
NZ (1) | NZ600229A (fr) |
PE (1) | PE20121509A1 (fr) |
PL (1) | PL2507235T3 (fr) |
PT (1) | PT2507235E (fr) |
RS (1) | RS53670B1 (fr) |
SI (1) | SI2507235T1 (fr) |
TN (1) | TN2012000265A1 (fr) |
UA (1) | UA108486C2 (fr) |
WO (1) | WO2011063908A1 (fr) |
ZA (1) | ZA201203806B (fr) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2343297A1 (fr) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
EP2343294A1 (fr) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines substituées |
UY33452A (es) * | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
WO2012080229A1 (fr) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | Imidazopyrazines pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperprolifération |
US20140135319A1 (en) | 2010-12-17 | 2014-05-15 | Bayer Intellectual Property Gmbh | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
EP2651946B1 (fr) | 2010-12-17 | 2015-05-27 | Bayer Intellectual Property GmbH | Imidazopyrazines 2-substituées pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperprolifération |
CA2821817A1 (fr) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | 6-imidazopyrazines substituees pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperproliferation |
ES2530802T3 (es) | 2010-12-17 | 2015-03-06 | Bayer Ip Gmbh | Imidazopirazinas 6-tiosustituidas para uso como inhibidores de MPS-1 y TKK en el tratamiento de trastornos hiperproliferativos |
US20140187548A1 (en) | 2010-12-17 | 2014-07-03 | Bayer Intellectual Property Gmbh | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
JP6001049B2 (ja) | 2011-03-31 | 2016-10-05 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | Mps−1キナーゼ阻害剤としての置換ベンズイミダゾール類 |
US20140255392A1 (en) | 2011-04-06 | 2014-09-11 | Bayer Intellectual Property Gmbh | Substituted imidazopyridines and intermediates thereof |
MX348783B (es) * | 2011-04-21 | 2017-06-28 | Bayer Ip Gmbh | Triazolopiridinas. |
WO2012160029A1 (fr) | 2011-05-23 | 2012-11-29 | Bayer Intellectual Property Gmbh | Triazolopyridines substituées |
UA112096C2 (uk) | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
CA2867061A1 (fr) | 2012-03-14 | 2013-09-19 | Bayer Intellectual Property Gmbh | Imidazopyridazines substituees |
EP2872506A1 (fr) * | 2012-07-10 | 2015-05-20 | Bayer Pharma Aktiengesellschaft | Procédé de préparation de triazolopyridines substituées |
WO2014020041A1 (fr) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinaisons pour le traitement du cancer |
WO2014020043A1 (fr) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinaisons pour le traitement du cancer |
CN104936956A (zh) | 2013-01-30 | 2015-09-23 | 拜耳制药股份公司 | 氨基取代的异噻唑 |
AR096469A1 (es) * | 2013-06-06 | 2015-12-30 | Bayer Pharma AG | Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas |
CA2914516A1 (fr) * | 2013-06-07 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Triazolopyridines substituees |
DK3008062T3 (en) * | 2013-06-11 | 2017-06-12 | Bayer Pharma AG | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES |
CN105283178A (zh) | 2013-06-11 | 2016-01-27 | 拜耳制药股份公司 | 用于治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合 |
EP2980088A1 (fr) | 2014-07-28 | 2016-02-03 | Bayer Pharma Aktiengesellschaft | Isothiazoles substitués d'amine |
KR102432420B1 (ko) | 2014-04-07 | 2022-08-17 | 네덜런즈 트랜슬레이셔널 리서치 센터 비.브이. | (5,6-디하이드로)피리미도[4,5-e]인돌리진 |
EP2977377A1 (fr) | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Isoxazoles substitués par amino |
EP2977376A1 (fr) | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Isoxazoles substitués par amino |
EP2977375A1 (fr) | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Isoxazoles substitués par amino |
CN107567503B (zh) | 2015-04-17 | 2022-03-22 | 荷兰转化研究中心有限责任公司 | 用于ttk抑制剂化疗的预后生物标记 |
KR101686411B1 (ko) * | 2015-12-28 | 2016-12-14 | 한국원자력의학원 | 피리딘계 유도체를 포함하는 암 예방 또는 치료용 조성물 |
CN107641118B (zh) * | 2016-07-22 | 2020-11-06 | 爱科诺生物医药股份有限公司 | 具有细胞坏死抑制活性的化合物及其组合物和应用 |
JP7023217B2 (ja) | 2017-12-01 | 2022-02-21 | ダイキン工業株式会社 | アルカリ接触する表面を有する構成要素 |
US20230391768A2 (en) * | 2018-11-07 | 2023-12-07 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
US20240123043A1 (en) * | 2021-02-22 | 2024-04-18 | Orgenesis Inc. | Pharmaceutical compositions comprising ranpirnase |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
EP1646382A4 (fr) | 2003-06-30 | 2010-07-21 | Hif Bio Inc | Composes, compositions et procedes |
JP2008515874A (ja) | 2004-10-07 | 2008-05-15 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 抗菌薬 |
WO2007065010A2 (fr) | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Composes anti-angiogenese |
PT2029602E (pt) | 2006-05-31 | 2010-07-08 | Galapagos Nv | Compostos de triazolopirazina uteis para o tratamento de doenãas degenerativas e inflamatërias |
US8883820B2 (en) | 2006-08-30 | 2014-11-11 | Cellzome Ltd. | Triazole derivatives as kinase inhibitors |
CA2693232A1 (fr) * | 2007-07-18 | 2009-01-22 | Novartis Ag | Composes heteroaryliques bicycliques et leur utilisation comme inhibiteurs de kinase |
EA201000341A1 (ru) * | 2007-08-23 | 2010-10-29 | Астразенека Аб | 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений |
WO2009027283A1 (fr) * | 2007-08-31 | 2009-03-05 | Merck Serono S.A. | Composés de triazolopyridine et leur utilisation comme inhibiteurs de ask |
GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
AU2008328882A1 (en) | 2007-11-27 | 2009-06-04 | Cellzome Limited | Amino triazoles as PI3K inhibitors |
WO2010092015A1 (fr) | 2009-02-10 | 2010-08-19 | Cellzome Limited | Dérivés d'urée-triazolo[1,5-a]pyridine en tant qu'inhibiteurs de pi3k |
KR20110116160A (ko) * | 2009-02-13 | 2011-10-25 | 포비어 파마수티칼스 | 카이네이스 저해제로서의 〔1,2,4〕트리아졸로〔1,5-a〕피리딘 |
ES2547328T3 (es) | 2009-04-29 | 2015-10-05 | Bayer Intellectual Property Gmbh | Imidazoquinoxalinas sustituidas |
JP5728683B2 (ja) | 2009-09-04 | 2015-06-03 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン |
EP2343297A1 (fr) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
EP2343294A1 (fr) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines substituées |
EP2343295A1 (fr) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Dérivés de triazolopyridine |
KR20120123677A (ko) | 2010-01-15 | 2012-11-09 | 얀센 파마슈티칼즈, 인코포레이티드 | 감마 세크레타제 조절제로서의 신규 치환된 비사이클릭 트리아졸 유도체 |
US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
-
2009
- 2009-11-30 EP EP09075535A patent/EP2343297A1/fr not_active Withdrawn
-
2010
- 2010-11-17 EA EA201200794A patent/EA022353B1/ru not_active IP Right Cessation
- 2010-11-17 SI SI201030810T patent/SI2507235T1/sl unknown
- 2010-11-17 JP JP2012541336A patent/JP5805653B2/ja not_active Expired - Fee Related
- 2010-11-17 DK DK10787274.9T patent/DK2507235T3/en active
- 2010-11-17 EP EP10787274.9A patent/EP2507235B1/fr active Active
- 2010-11-17 WO PCT/EP2010/006994 patent/WO2011063908A1/fr active Application Filing
- 2010-11-17 CU CU2012000084A patent/CU24100B1/es active IP Right Grant
- 2010-11-17 KR KR1020127016940A patent/KR20120115290A/ko not_active Application Discontinuation
- 2010-11-17 MY MYPI2012002378A patent/MY160325A/en unknown
- 2010-11-17 RS RS20140646A patent/RS53670B1/en unknown
- 2010-11-17 BR BR112012012906A patent/BR112012012906A2/pt not_active IP Right Cessation
- 2010-11-17 PT PT107872749T patent/PT2507235E/pt unknown
- 2010-11-17 CA CA2781915A patent/CA2781915A1/fr not_active Abandoned
- 2010-11-17 MX MX2012006252A patent/MX2012006252A/es active IP Right Grant
- 2010-11-17 AU AU2010324155A patent/AU2010324155B2/en not_active Ceased
- 2010-11-17 UA UAA201207609A patent/UA108486C2/uk unknown
- 2010-11-17 ES ES10787274.9T patent/ES2525069T3/es active Active
- 2010-11-17 NZ NZ600229A patent/NZ600229A/en not_active IP Right Cessation
- 2010-11-17 US US13/512,701 patent/US9676766B2/en not_active Expired - Fee Related
- 2010-11-17 CN CN201080061524.1A patent/CN102762557B/zh not_active Expired - Fee Related
- 2010-11-17 PE PE2012000742A patent/PE20121509A1/es not_active Application Discontinuation
- 2010-11-17 PL PL10787274T patent/PL2507235T3/pl unknown
- 2010-11-30 AR ARP100104406A patent/AR079166A1/es unknown
-
2012
- 2012-05-13 IL IL219750A patent/IL219750A/en not_active IP Right Cessation
- 2012-05-24 ZA ZA2012/03806A patent/ZA201203806B/en unknown
- 2012-05-25 TN TNP2012000265A patent/TN2012000265A1/en unknown
- 2012-05-28 MA MA34899A patent/MA33768B1/fr unknown
- 2012-05-30 CL CL2012001391A patent/CL2012001391A1/es unknown
- 2012-05-30 EC ECSP12011935 patent/ECSP12011935A/es unknown
- 2012-05-30 CR CR20120295A patent/CR20120295A/es unknown
- 2012-05-30 GT GT201200165A patent/GT201200165A/es unknown
- 2012-05-30 HN HN2012001162A patent/HN2012001162A/es unknown
- 2012-05-30 DO DO2012000150A patent/DOP2012000150A/es unknown
-
2013
- 2013-04-27 HK HK13105127.0A patent/HK1178153A1/zh not_active IP Right Cessation
-
2014
- 2014-11-11 HR HRP20141093AT patent/HRP20141093T1/hr unknown
- 2014-11-21 CY CY20141100970T patent/CY1115866T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33768B1 (fr) | Triazolopyridines | |
TN2014000254A1 (en) | Substituted triazolopyridines and their use as ttk inhibitors | |
JO3040B1 (ar) | ترايازولوبيريدينات | |
EA201290183A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
MX2009000884A (es) | Derivados de piridizinona. | |
SV2008003045A (es) | Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes | |
MA32175B1 (fr) | Oxadiazoanthracènes pour le traitement du diabète | |
GEP20146102B (en) | Compounds and compositions as protein kinase inhibitors | |
GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
UA108743C2 (uk) | Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази | |
MX346336B (es) | Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa. | |
TW200745122A (en) | New compounds I | |
UA98804C2 (ru) | Катехоламиновые производные и фармацевтическая композиция на их основе | |
GEP20135744B (en) | Quinuclidine carbonate derivatives and medicinal compositions containing the same | |
MA32776B1 (fr) | Inhibiteurs de l'akt et de la p70 s6 kinase | |
MX2012005225A (es) | Compuestos y composiciones de purina n-7 sustituida y pirazolopirimidina, y metodos de uso. | |
SG158091A1 (en) | Imidazoazepinone compounds | |
WO2008074803A3 (fr) | Composés | |
MX2011013869A (es) | Agentes antihelminticos y su uso. | |
EA201000703A1 (ru) | Производные пиразола в качестве ингибиторов 5-lo | |
TW200745133A (en) | New compounds II | |
GB0514811D0 (en) | Compounds | |
GB0609897D0 (en) | Compounds | |
DE602007007934D1 (en) | Imidazoazephinonverbindungen |